Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on HPV-Linked throat cancer

NCT ID NCT03799445

Summary

This study is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a targeted course of radiation is safe and effective for treating advanced throat cancer caused by HPV. The goal is to help the body's immune system better recognize and attack the cancer cells while using radiation to shrink tumors. It is for patients with a specific type and stage of HPV-positive throat cancer who have not had prior treatment for it.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE I HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.